Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease

Table 2 Various studies examining the incidence/recurrence of non-alcoholic fatty liver disease (de novo or recurrent), non-alcoholic steatohepatitis and Cirrhosis in the post-liver transplant population n (%)

Ref.	Year of publication	Indication of transplant	Number of patients	Findings of NAFLD post-transplant	Findings of NASH post-transplant	Findings of cirrhosispost-transplant	Mean follow-up duration
Tanaka et al[66]	2013	Living donor transplant for NAFLD	7	0 (0)	1 (14)	None	5.3 yr
Dureja et al[59]	2011	NAFLD	88	34 (39)	25 (28.4)	3 (3.4) (reported as fibrosis grade 3/4)	82 mo
Dumortier et al[60]	2010	Several indication	599	131 (31.1)	5 (3.8)	3 (2.25)	40 mo
Bhagat et al[61]	2009	Cryptogenic/NASH Cirrhosis vs alcoholic cirrhosis	71	N/A	31 (33)	None	1517 d
Lim et al[62]	2007	Non-NAFLD indication (18 HBV, 7 HCV, 5 others)	30	12 (40)	4 (13)	None	44 mo
Seo et al[63]	2007	68 various causes, 84% HCV	68	121 (18)	61 (9)	None	28 mo
Ong et al[64]	2001	Cryptogenic cirrhosis	51	13 (25.4)	8 (15.7)	None	26 mo
Contos et al[57]	2001	Cryptogenic/NASH cirrhosis	30	30 (100)	3 (10)	None	3.5 yr
Charlton et al[65]	2001	NASH cirrhosis	16	9 (60)	5 (33)	2 (12.5)	28.1 mo

¹De novo. HCV: Hepatitis C virus; HBV: Hepatitis B virus; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.